By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
Videos
Stocks slide as Middle East tensions rise, energy shares gain, crypto portfolio tips
19 hours ago
Videos
Why 3D printed houses are on the rise
20 hours ago
News
Crown Castle Inc. 2025 Q2 – Results – Earnings Call Presentation (NYSE:CCI)
20 hours ago
Videos
What a trillion-dollar defense budget really means for veterans
2 days ago
Videos
The New Soap Operas Are Just 2 Minutes Long — The Power Of Micro Dramas
2 days ago
News
Microsoft poaches top Google DeepMind staff in AI talent war
2 days ago
Videos
Most Americans can’t answer basic retirement questions: Survey
3 days ago
Videos
How Airbus beat Boeing to become the world’s biggest plane maker
3 days ago
News
White Brook Capital Partners Q2 2025 Commentary
3 days ago
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Eli Lilly to seek US approval after Alzheimer’s drug trial success
News

Eli Lilly to seek US approval after Alzheimer’s drug trial success

News Room
Last updated: 2023/05/03 at 12:08 PM
By News Room
Share
4 Min Read
SHARE

Eli Lilly will apply for regulatory approval of an Alzheimer’s drug that a clinical study showed can slow the progress of cognitive decline in patients in the early stages, raising hopes for a new treatment to manage the disease.

For patients in a late-stage trial, the drug called donanemab slowed progression of the disease by 35 per cent compared with those who took the placebo during an 18-month treatment period. The decline in patients’ ability to perform daily tasks was 40 per cent lower for those on the drug.

However, the drug displayed severe side effects such as brain swelling and bleeding and three people on the trial died from these effects.

The results of the closely watched trial mark the second significant breakthrough in a year for a drug aiming to treat a disease with about 50mn sufferers worldwide.

US regulators in January approved one of the first new treatment for Alzheimer’s in decades when they gave the green light to lecanemab, a drug co-developed by Japanese drugmaker Eisai and US biotech Biogen.

Both of the drugs work by reducing the build-up of sticky plaques in the brain known as beta-amyloid, which are at the centre of an acrimonious scientific debate about what causes Alzheimer’s disease.

Patient uptake of lecanemab remains very low due to its high price tag — $26,500 a year — and tough restrictions on reimbursement by US government-funded health schemes. Negotiations on government reimbursement, which are critical to the drug’s success, are continuing.

Michael Yee, analyst at Jefferies, said the strong efficacy shown by Lilly’s drug should help persuade US government officials to allow public-funded insurance policies to reimburse the new class of drugs, which treat Alzheimer’s by reducing amyloid plaques.

“It should leave little doubt in minds that these amyloid-lowering drugs have good efficacy for patients and further de-risk the amyloid hypothesis for Alzheimer’s,” said Yee, adding that it would lead to more long-term uptake of both drugs.

Shares in Lilly climbed more than 4 per cent on Wednesday, while Biogen shares rose nearly 2 per cent.

The Alzheimer’s Association said the results from the Lilly trial were the “strongest” released to date for an Alzheimer’s drug and suggested an “inflection point” for treatment of the disease.

Lilly said the Trailblazer-Alz 2 trial met all its goals and that it would apply for regulatory approval to the US Food and Drug Administration before the end of June. The trial enrolled 1,182 people with early-stage Alzheimer’s, and 552 people with a later stage of the disease.

When both of these groups were combined, donanemab slowed progress of the disease by 22 per cent.

Lilly’s chief executive David Ricks told CNBC he expected full approval of donanemab by the end of the year and it would be priced at a similar range as other Alzheimer’s treatments.

Read the full article here

News Room May 3, 2023 May 3, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Stocks slide as Middle East tensions rise, energy shares gain, crypto portfolio tips

Watch full video on YouTube

Why 3D printed houses are on the rise

Watch full video on YouTube

Crown Castle Inc. 2025 Q2 – Results – Earnings Call Presentation (NYSE:CCI)

This article was written byFollowSeeking Alpha's transcripts team is responsible for the…

What a trillion-dollar defense budget really means for veterans

Watch full video on YouTube

The New Soap Operas Are Just 2 Minutes Long — The Power Of Micro Dramas

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

News

Crown Castle Inc. 2025 Q2 – Results – Earnings Call Presentation (NYSE:CCI)

By News Room
News

Microsoft poaches top Google DeepMind staff in AI talent war

By News Room
News

White Brook Capital Partners Q2 2025 Commentary

By News Room
News

EU must strengthen Asian security ties despite US pressure, says Kaja Kallas

By News Room
News

US embassy in China warns exit bans risk straining bilateral relations

By News Room
News

Client Challenge

By News Room
News

Donald Trump’s escalating attacks on Federal Reserve unnerve investors

By News Room
News

Spain overtakes Germany as top EU asylum destination

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?